Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.

Next Previous
X
Search
Trial Profile

A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 01 Apr 2018 Results of pooled data from vitro compared with nine clinical trial assessing PK exposure to tiotropium in preschool children with persistent asthmatic symptoms (using test VHC), were published in the Respiratory Medicine.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top